Skip to content
Biodatica
Start free

Investigator

Jean-Pierre J. Issa

CORIELL INSTITUTE FOR MEDICAL RESEARCH · funded by NCI

Companies
2

Resolved onto their grants.

Grants
6

Federal awards on file.

Non-dilutive funding
$3.9M

Summed across those awards.

First award
Aug 16, 2021

On this record.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. P50

    Cyclin Dependent Kinases as Epigenetic Therapy Targets

    $536k

    Aug 16, 2021NCICORIELL INSTITUTE FOR MEDICAL RESEARCHNIH RePORTER · 11140520 (opens the source filing in a new tab)

  2. P50

    Genomics Core

    $249k

    Aug 16, 2021NCICORIELL INSTITUTE FOR MEDICAL RESEARCHNIH RePORTER · 11140517 (opens the source filing in a new tab)

  3. P50

    Career Enhancement Program

    $89k

    Aug 16, 2021NCICORIELL INSTITUTE FOR MEDICAL RESEARCHNIH RePORTER · 11140527 (opens the source filing in a new tab)

  4. P50

    Developmental Research Program

    $89k

    Aug 16, 2021NCICORIELL INSTITUTE FOR MEDICAL RESEARCHNIH RePORTER · 11140526 (opens the source filing in a new tab)

  5. P50

    Admin Core

    $430k

    Aug 16, 2021NCICORIELL INSTITUTE FOR MEDICAL RESEARCHNIH RePORTER · 11140515 (opens the source filing in a new tab)

  6. P50

    Epigenetic Therapies - New Approaches

    $2.5M

    Aug 16, 2021NCICORIELL INSTITUTE FOR MEDICAL RESEARCHNIH RePORTER · 11140513 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources